Effect of H. Pylori Eradication on The Improvement of Gastrointestinal Symptoms
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAmany Usama Ahmed Arafa
About this trial
This study aims to evaluate the effect of Helicobacter pylori eradication on gastrointestinal symptoms in adult patients. H. pylori infection is a common cause of dyspepsia and other upper gastrointestinal complaints. The trial will assess whether successful eradication therapy leads to significant improvement in symptoms compared to baseline. Adult patients diagnosed with H. pylori infection will receive standard eradication treatment, and symptom changes will be monitored using validated questionnaires over a defined follow-up period.
Eligibility criteria
Qualifiers
Adults aged 18 years and older.
Confirmed diagnosis of Helicobacter pylori infection by one or more diagnostic tests.
Presence of any upper or lower gastrointestinal symptoms.
Willingness to undergo H. Pylori eradication therapy and follow-up.
Disqualifiers
Age less than 18 years.
The previously unsuccessful application of empirical H. pylori eradication therapy.
Use of non-steroidal anti-inflammatory drugs (NSAIDs).
Any malignant disease of the stomach or any other site.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
100 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Amany Usama Ahmed Arafa
Lead sponsor
Sohag University
Sponsor institution
Source ClinicalTrials.gov